Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Trastuzumab Emtansine”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01976169
What this trial is testing

Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)

Who this might be right for
Advanced Breast Cancer
University of Texas Southwestern Medical Center 29
Testing effectiveness (Phase 2)Looking for participantsNCT05408845
What this trial is testing

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Who this might be right for
Metastatic Salivary Gland CarcinomaRecurrent Salivary Gland CarcinomaStage III Major Salivary Gland Cancer AJCC v8+2 more
NRG Oncology 146
Large-scale testing (Phase 3)Looking for participantsNCT06830889
What this trial is testing

BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy

Who this might be right for
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 1,450
Testing effectiveness (Phase 2)Study completedNCT03530696
What this trial is testing

T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer

Who this might be right for
HER2-positive Breast CancerBreast CancerBreast Cancer Stage+3 more
University of Arizona 55
Early research (Phase 1)Study completedNCT04509596
What this trial is testing

DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer Metastatic
Dizal Pharmaceuticals 23
Not applicableLooking for participantsNCT06693037
What this trial is testing

Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy

Who this might be right for
HER2-positive Breast Cancer
Shu Wang 2,092
Testing effectiveness (Phase 2)Study completedNCT00509769
What this trial is testing

Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 112
Large-scale testing (Phase 3)Study completedNCT02131064
What this trial is testing

A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Who this might be right for
Breast Neoplasms
Hoffmann-La Roche 444
Testing effectiveness (Phase 2)Study completedNCT00875979
What this trial is testing

Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Who this might be right for
Metastatic Breast Cancer
Hoffmann-La Roche 67
Large-scale testing (Phase 3)Looking for participantsNCT06313086
What this trial is testing

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 442
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439110
What this trial is testing

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 38
Not applicableActive Not RecruitingNCT05889988
What this trial is testing

Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients

Who this might be right for
Breast Neoplasm
Mayo Clinic 36
Early research (Phase 1)Study completedNCT02562378
What this trial is testing

T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
MedSIR 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT05323955
What this trial is testing

Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib

Who this might be right for
Brain MetastasesHuman Epidermal Growth Factor 2 Positive Carcinoma of BreastAdvanced Breast Cancer
Carey Anders, M.D. 48
Large-scale testing (Phase 3)UnknownNCT05755048
What this trial is testing

FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 314
Not applicableNo Longer AvailableNCT01120561
What this trial is testing

Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc.
Large-scale testing (Phase 3)Looking for participantsNCT07673029
What this trial is testing

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
GeneQuantum Healthcare (Suzhou) Co., Ltd. 228
Early research (Phase 1)Study completedNCT02038010
What this trial is testing

BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx

Who this might be right for
HER2-positive Breast CancerRecurrent Breast CancerStage IIIA Breast Cancer+3 more
Northwestern University 17
Testing effectiveness (Phase 2)Looking for participantsNCT05673928
What this trial is testing

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

Who this might be right for
Metastatic Solid TumorBrain Metastases
M.D. Anderson Cancer Center 30
Large-scale testing (Phase 3)Active Not RecruitingNCT03975647
What this trial is testing

Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer 466
Next Page